Abstract
The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.
Original language | English (US) |
---|---|
Pages (from-to) | 374-380 |
Number of pages | 7 |
Journal | Gynecologic oncology |
Volume | 151 |
Issue number | 2 |
DOIs | |
State | Published - Nov 2018 |
Keywords
- Adoptive cell therapy
- Checkpoint inhibitor
- Clinical trials
- Immune-related adverse events
- Immunotherapy
- Targeted therapy
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynecology